Effect of P-selectin Monoclonal Antibody on Metastasis of Gastric Cancer and Immune Function

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2003 Jul 11

PMID 12854175

Citations 11

Authors

Jin-Lian Chen

Wei-Xiong Chen

Jin-Shui Zhu

Ni-Wei Chen

Tong Zhou

Ming Yao

Dong-Qing Zhang

Yun-Lin Wu

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the effect of cell adhesion molecule P-selectin monoclonal antibody (Mab) on metastasis and immune function of mice orthototopically implanted with human gastric cancer tissue.

Methods: SCID mice were implanted orthotopically with SGC-7901 human gastric carcinoma tissue. Starting from day 3 after operation, animals were given intravenously PBS or P-selectin Mab (100 microg/injection) (for both normal mice and tumor-implanted mice with tumors), twice weekly for 3 weeks. Two animals in each group were sacrificed randomly at the 1st, 2nd, 4th week and 6th week. While T cell and B cell transformation indices were determined with the (3)H TdR infiltration method, the NK cell activity was detected by the LDH release method.

Results: The metastatic rate in the P-selectin Mab treated group was lower than that in the PBS treated group (with tumors). The NK activity of normal mice increased over time. The immune functions (T, B cell function, NK activity) of the tumor group in the 6th week were significantly lower than those in the 4th week, but the change was attenuated by P-selectin Mab.

Conclusion: P-selectin Mab could suppress the metastasis of gastric cancer with no adverse effect on host immune function.

Citing Articles

Transcriptome Profile of Thyroid Glands in Bile Duct Ligation Mouse Model.

Jo D, Kim H, Kim Y, Song J Int J Mol Sci. 2022; 23(15).

PMID: 35897811 PMC: 9332885. DOI: 10.3390/ijms23158244.

Targeting Tumor Cells with Nanoparticles for Enhanced Co-Drug Delivery in Cancer Treatment.

Huang W, Lai C, Peng S, Hsu C, Hsu P, Chu P Pharmaceutics. 2021; 13(9).

PMID: 34575403 PMC: 8465501. DOI: 10.3390/pharmaceutics13091327.

PSGL-1 Immune Checkpoint Inhibition for CD4 T Cell Cancer Immunotherapy.

DeRogatis J, Viramontes K, Neubert E, Tinoco R Front Immunol. 2021; 12:636238.

PMID: 33708224 PMC: 7940186. DOI: 10.3389/fimmu.2021.636238.

Endothelial cells in colorectal cancer.

Chen W, Jiang J, Yu X, Xia W, Yu P, Wang K World J Gastrointest Oncol. 2019; 11(11):946-956.

PMID: 31798776 PMC: 6883186. DOI: 10.4251/wjgo.v11.i11.946.

Antithrombotic Agents and Cancer.

Bruno A, Dovizio M, Tacconelli S, Contursi A, Ballerini P, Patrignani P Cancers (Basel). 2018; 10(8).

PMID: 30065215 PMC: 6115803. DOI: 10.3390/cancers10080253.

References

MURAHASHI K, Yashiro M, Takenaka C, Matsuoka T, Ohira M, Chung K . Establishment of a new scirrhous gastric cancer cell line with loss of heterozygosity at E-cadherin locus. Int J Oncol. 2001; 19(5):1029-33. DOI: 10.3892/ijo.19.5.1029. View

Berdichevsky Y, Zemel R, Bachmatov L, Abramovich A, Koren R, Sathiyamoorthy P . A novel high throughput screening assay for HCV NS3 serine protease inhibitors. J Virol Methods. 2002; 107(2):245-55. DOI: 10.1016/s0166-0934(02)00255-0. View

Harn H, Shen K, Liu C, HO L, Yang L, Yueh K . Hyaluronate binding assay study of transfected CD44 V4-V7 isoforms into the human gastric carcinoma cell line SC-M1. J Pathol. 1998; 184(3):291-6. DOI: 10.1002/(SICI)1096-9896(199803)184:3<291::AID-PATH1>3.0.CO;2-O. View

Park C, Shin Y, Kim T, Park S, Ahn G . High CD99 expression in memory T and B cells in reactive lymph nodes. J Korean Med Sci. 2000; 14(6):600-6. PMC: 3054445. DOI: 10.3346/jkms.1999.14.6.600. View

Nollet F, Berx G, VAN Roy F . The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun. 1999; 2(2):77-85. DOI: 10.1006/mcbr.1999.0155. View

Castella E, Ariza A, Pellicer I, Fernandez-Vasalo A, Ojanguren I . Differential expression of CD44v6 in metastases of intestinal and diffuse types of gastric carcinoma. J Clin Pathol. 1998; 51(2):134-7. PMC: 500508. DOI: 10.1136/jcp.51.2.134. View

Saito H, Tsujitani S, Katano K, Ikeguchi M, Maeta M, Kaibara N . Serum concentration of CD44 variant 6 and its relation to prognosis in patients with gastric carcinoma. Cancer. 1998; 83(6):1094-101. View

Ikonen T, Matikainen M, Mononen N, Hyytinen E, Helin H, Tommola S . Association of E-cadherin germ-line alterations with prostate cancer. Clin Cancer Res. 2001; 7(11):3465-71. View

Koyama S, Maruyama T, Adachi S . Expression of epidermal growth factor receptor and CD44 splicing variants sharing exons 6 and 9 on gastric and esophageal carcinomas: a two-color flow-cytometric analysis. J Cancer Res Clin Oncol. 1999; 125(1):47-54. DOI: 10.1007/s004320050241. View

10.

Hofler H . [Diffuse stomach carcinoma: from H&E diagnosis and molecular pathology to specific therapy]. Verh Dtsch Ges Pathol. 2000; 83:148-54. View

11.

Sato S, Yokozaki H, Yasui W, Nikai H, Tahara E . Silencing of the CD44 gene by CpG methylation in a human gastric carcinoma cell line. Jpn J Cancer Res. 1999; 90(5):485-9. PMC: 5926100. DOI: 10.1111/j.1349-7006.1999.tb00773.x. View

12.

Luber B, Candidus S, HANDSCHUH G, Mentele E, Hutzler P, Feller S . Tumor-derived mutated E-cadherin influences beta-catenin localization and increases susceptibility to actin cytoskeletal changes induced by pervanadate. Cell Adhes Commun. 2000; 7(5):391-408. DOI: 10.3109/15419060009109021. View

13.

Sandborn W, Targan S . Biologic therapy of inflammatory bowel disease. Gastroenterology. 2002; 122(6):1592-608. DOI: 10.1053/gast.2002.33426. View

14.

Koshikawa N, Moriyama K, Takamura H, Mizushima H, Nagashima Y, Yanoma S . Overexpression of laminin gamma2 chain monomer in invading gastric carcinoma cells. Cancer Res. 1999; 59(21):5596-601. View

15.

Okada Y, Fujiwara Y, Yamamoto H, Sugita Y, Yasuda T, Doki Y . Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple-marker reverse transcriptase-polymerase chain reaction assay. Cancer. 2001; 92(8):2056-64. DOI: 10.1002/1097-0142(20011015)92:8<2056::aid-cncr1545>3.0.co;2-l. View

16.

Schuhmacher C, Becker K, Reich U, Schenk U, Mueller J, Siewert J . Rapid detection of mutated E-cadherin in peritoneal lavage specimens from patients with diffuse-type gastric carcinoma. Diagn Mol Pathol. 1999; 8(2):66-70. DOI: 10.1097/00019606-199906000-00002. View

17.

Futamura N, Nakamura S, Tatematsu M, Yamamura Y, Kannagi R, Hirose H . Clinicopathologic significance of sialyl Le(x) expression in advanced gastric carcinoma. Br J Cancer. 2000; 83(12):1681-7. PMC: 2363447. DOI: 10.1054/bjoc.2000.1484. View

18.

Shun C, Wu M, Lin M, Chang M, Lin J, Chuang S . Immunohistochemical evaluation of cadherin and catenin expression in early gastric carcinomas: correlation with clinicopathologic characteristics and Helicobacter pylori infection. Oncology. 2001; 60(4):339-45. DOI: 10.1159/000058530. View

19.

Yanagimoto K, Sato Y, Shimoyama Y, Tsuchiya B, Kuwao S, Kameya T . Co-expression of N-cadherin and alpha-fetoprotein in stomach cancer. Pathol Int. 2001; 51(8):612-8. DOI: 10.1046/j.1440-1827.2001.01248.x. View

20.

Taniuchi K, Takata M, Matsui C, Fushida Y, Uchiyama K, Mori T . Antiepiligrin (laminin 5) cicatricial pemphigoid associated with an underlying gastric carcinoma producing laminin 5. Br J Dermatol. 1999; 140(4):696-700. DOI: 10.1046/j.1365-2133.1999.02773.x. View